Financhill
Sell
25

PRPH Quote, Financials, Valuation and Earnings

Last price:
$0.38
Seasonality move :
5.24%
Day range:
$0.37 - $0.42
52-week range:
$0.22 - $3.43
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
2.02x
P/B ratio:
1.02x
Volume:
1M
Avg. volume:
2.9M
1-year change:
-88.66%
Market cap:
$15.5M
Revenue:
$6.8M
EPS (TTM):
-$2.16

Price Performance History

Performance vs. Valuation Benchmarks

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Competitors

Company Revenue Forecast Earnings Forecast Revenue Growth Forecast Earnings Growth Forecast Analyst Price Target Median
PRPH
ProPhase Labs
$3.6M -$0.15 3.99% -50% $13.80
APDN
Applied DNA Sciences
$1.3M -$37.50 27.47% -98.87% --
FONR
Fonar
-- -- -- -- --
IMDX
Insight Molecular Diagnostics
$292K -$0.24 180.72% -33.33% --
VCYT
Veracyte
$120.9M $0.30 6.44% 332.6% $40.33
XWEL
XWELL
-- -- -- -- --
Company Price Analyst Target Market Cap P/E Ratio Dividend per Share Dividend Yield Price / LTM Sales
PRPH
ProPhase Labs
$0.37 $13.80 $15.5M -- $0.00 0% 2.02x
APDN
Applied DNA Sciences
$5.03 -- $2.6M -- $0.00 0% 0.06x
FONR
Fonar
$16.09 -- $101.3M 12.87x $0.00 0% 0.99x
IMDX
Insight Molecular Diagnostics
$2.83 -- $80.9M -- $0.00 0% 12.83x
VCYT
Veracyte
$25.17 $40.33 $2B 61.39x $0.00 0% 4.30x
XWEL
XWELL
$1.02 -- $5.4M -- $0.00 0% 0.15x
Company Total Debt / Total Capital Beta Debt to Equity Quick Ratio
PRPH
ProPhase Labs
22.08% -3.124 25.51% 0.84x
APDN
Applied DNA Sciences
-- 5.076 -- 3.97x
FONR
Fonar
-- 1.699 -- 9.69x
IMDX
Insight Molecular Diagnostics
-- -1.933 -- 3.57x
VCYT
Veracyte
-- 2.266 -- 4.54x
XWEL
XWELL
-- 0.204 -- 1.41x
Company Gross Profit Operating Income Return on Invested Capital Return on Common Equity EBIT Margin Free Cash Flow
PRPH
ProPhase Labs
$526K -$3.7M -101.67% -144.22% -289.24% -$3.4M
APDN
Applied DNA Sciences
$370.9K -$3.5M -84.02% -84.02% -352.03% -$3.4M
FONR
Fonar
$12.1M $3.7M 5.32% 5.33% 15.23% $2.5M
IMDX
Insight Molecular Diagnostics
$1.3M -$5.9M -693.81% -693.81% -310.66% -$6.2M
VCYT
Veracyte
$79.5M $1.2M 2.85% 2.85% 1.02% $3.5M
XWEL
XWELL
$1.3M -$3.2M -153.74% -153.74% -64.9% -$4.6M

ProPhase Labs vs. Competitors

  • Which has Higher Returns PRPH or APDN?

    Applied DNA Sciences has a net margin of -209.38% compared to ProPhase Labs's net margin of -336%. ProPhase Labs's return on equity of -144.22% beat Applied DNA Sciences's return on equity of -84.02%.

    Company Gross Margin Earnings Per Share Invested Capital
    PRPH
    ProPhase Labs
    36.76% $0.11 $19.4M
    APDN
    Applied DNA Sciences
    37.71% -$230.25 $10.2M
  • What do Analysts Say About PRPH or APDN?

    ProPhase Labs has a consensus price target of $13.80, signalling upside risk potential of 3609.68%. On the other hand Applied DNA Sciences has an analysts' consensus of -- which suggests that it could grow by 447215.88%. Given that Applied DNA Sciences has higher upside potential than ProPhase Labs, analysts believe Applied DNA Sciences is more attractive than ProPhase Labs.

    Company Buy Ratings Hold Ratings Sell Ratings
    PRPH
    ProPhase Labs
    0 0 0
    APDN
    Applied DNA Sciences
    0 1 0
  • Is PRPH or APDN More Risky?

    ProPhase Labs has a beta of -0.412, which suggesting that the stock is 141.195% less volatile than S&P 500. In comparison Applied DNA Sciences has a beta of 0.068, suggesting its less volatile than the S&P 500 by 93.226%.

  • Which is a Better Dividend Stock PRPH or APDN?

    ProPhase Labs has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Applied DNA Sciences offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. ProPhase Labs pays -- of its earnings as a dividend. Applied DNA Sciences pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios PRPH or APDN?

    ProPhase Labs quarterly revenues are $1.4M, which are larger than Applied DNA Sciences quarterly revenues of $983.4K. ProPhase Labs's net income of $4M is higher than Applied DNA Sciences's net income of -$3.3M. Notably, ProPhase Labs's price-to-earnings ratio is -- while Applied DNA Sciences's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for ProPhase Labs is 2.02x versus 0.06x for Applied DNA Sciences. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    PRPH
    ProPhase Labs
    2.02x -- $1.4M $4M
    APDN
    Applied DNA Sciences
    0.06x -- $983.4K -$3.3M
  • Which has Higher Returns PRPH or FONR?

    Fonar has a net margin of -209.38% compared to ProPhase Labs's net margin of 9.23%. ProPhase Labs's return on equity of -144.22% beat Fonar's return on equity of 5.33%.

    Company Gross Margin Earnings Per Share Invested Capital
    PRPH
    ProPhase Labs
    36.76% $0.11 $19.4M
    FONR
    Fonar
    44.52% $0.37 $160.3M
  • What do Analysts Say About PRPH or FONR?

    ProPhase Labs has a consensus price target of $13.80, signalling upside risk potential of 3609.68%. On the other hand Fonar has an analysts' consensus of -- which suggests that it could fall by --. Given that ProPhase Labs has higher upside potential than Fonar, analysts believe ProPhase Labs is more attractive than Fonar.

    Company Buy Ratings Hold Ratings Sell Ratings
    PRPH
    ProPhase Labs
    0 0 0
    FONR
    Fonar
    0 0 0
  • Is PRPH or FONR More Risky?

    ProPhase Labs has a beta of -0.412, which suggesting that the stock is 141.195% less volatile than S&P 500. In comparison Fonar has a beta of 0.998, suggesting its less volatile than the S&P 500 by 0.238%.

  • Which is a Better Dividend Stock PRPH or FONR?

    ProPhase Labs has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Fonar offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. ProPhase Labs pays -- of its earnings as a dividend. Fonar pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios PRPH or FONR?

    ProPhase Labs quarterly revenues are $1.4M, which are smaller than Fonar quarterly revenues of $27.2M. ProPhase Labs's net income of $4M is higher than Fonar's net income of $2.5M. Notably, ProPhase Labs's price-to-earnings ratio is -- while Fonar's PE ratio is 12.87x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for ProPhase Labs is 2.02x versus 0.99x for Fonar. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    PRPH
    ProPhase Labs
    2.02x -- $1.4M $4M
    FONR
    Fonar
    0.99x 12.87x $27.2M $2.5M
  • Which has Higher Returns PRPH or IMDX?

    Insight Molecular Diagnostics has a net margin of -209.38% compared to ProPhase Labs's net margin of -312.02%. ProPhase Labs's return on equity of -144.22% beat Insight Molecular Diagnostics's return on equity of -693.81%.

    Company Gross Margin Earnings Per Share Invested Capital
    PRPH
    ProPhase Labs
    36.76% $0.11 $19.4M
    IMDX
    Insight Molecular Diagnostics
    61.97% -$0.26 $10.2M
  • What do Analysts Say About PRPH or IMDX?

    ProPhase Labs has a consensus price target of $13.80, signalling upside risk potential of 3609.68%. On the other hand Insight Molecular Diagnostics has an analysts' consensus of -- which suggests that it could grow by 91.4%. Given that ProPhase Labs has higher upside potential than Insight Molecular Diagnostics, analysts believe ProPhase Labs is more attractive than Insight Molecular Diagnostics.

    Company Buy Ratings Hold Ratings Sell Ratings
    PRPH
    ProPhase Labs
    0 0 0
    IMDX
    Insight Molecular Diagnostics
    0 0 0
  • Is PRPH or IMDX More Risky?

    ProPhase Labs has a beta of -0.412, which suggesting that the stock is 141.195% less volatile than S&P 500. In comparison Insight Molecular Diagnostics has a beta of 0.953, suggesting its less volatile than the S&P 500 by 4.652%.

  • Which is a Better Dividend Stock PRPH or IMDX?

    ProPhase Labs has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Insight Molecular Diagnostics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. ProPhase Labs pays -- of its earnings as a dividend. Insight Molecular Diagnostics pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios PRPH or IMDX?

    ProPhase Labs quarterly revenues are $1.4M, which are smaller than Insight Molecular Diagnostics quarterly revenues of $2.1M. ProPhase Labs's net income of $4M is higher than Insight Molecular Diagnostics's net income of -$6.7M. Notably, ProPhase Labs's price-to-earnings ratio is -- while Insight Molecular Diagnostics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for ProPhase Labs is 2.02x versus 12.83x for Insight Molecular Diagnostics. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    PRPH
    ProPhase Labs
    2.02x -- $1.4M $4M
    IMDX
    Insight Molecular Diagnostics
    12.83x -- $2.1M -$6.7M
  • Which has Higher Returns PRPH or VCYT?

    Veracyte has a net margin of -209.38% compared to ProPhase Labs's net margin of 6.16%. ProPhase Labs's return on equity of -144.22% beat Veracyte's return on equity of 2.85%.

    Company Gross Margin Earnings Per Share Invested Capital
    PRPH
    ProPhase Labs
    36.76% $0.11 $19.4M
    VCYT
    Veracyte
    69.46% $0.09 $1.2B
  • What do Analysts Say About PRPH or VCYT?

    ProPhase Labs has a consensus price target of $13.80, signalling upside risk potential of 3609.68%. On the other hand Veracyte has an analysts' consensus of $40.33 which suggests that it could grow by 60.24%. Given that ProPhase Labs has higher upside potential than Veracyte, analysts believe ProPhase Labs is more attractive than Veracyte.

    Company Buy Ratings Hold Ratings Sell Ratings
    PRPH
    ProPhase Labs
    0 0 0
    VCYT
    Veracyte
    7 1 1
  • Is PRPH or VCYT More Risky?

    ProPhase Labs has a beta of -0.412, which suggesting that the stock is 141.195% less volatile than S&P 500. In comparison Veracyte has a beta of 2.071, suggesting its more volatile than the S&P 500 by 107.062%.

  • Which is a Better Dividend Stock PRPH or VCYT?

    ProPhase Labs has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Veracyte offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. ProPhase Labs pays -- of its earnings as a dividend. Veracyte pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios PRPH or VCYT?

    ProPhase Labs quarterly revenues are $1.4M, which are smaller than Veracyte quarterly revenues of $114.5M. ProPhase Labs's net income of $4M is lower than Veracyte's net income of $7M. Notably, ProPhase Labs's price-to-earnings ratio is -- while Veracyte's PE ratio is 61.39x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for ProPhase Labs is 2.02x versus 4.30x for Veracyte. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    PRPH
    ProPhase Labs
    2.02x -- $1.4M $4M
    VCYT
    Veracyte
    4.30x 61.39x $114.5M $7M
  • Which has Higher Returns PRPH or XWEL?

    XWELL has a net margin of -209.38% compared to ProPhase Labs's net margin of -67.19%. ProPhase Labs's return on equity of -144.22% beat XWELL's return on equity of -153.74%.

    Company Gross Margin Earnings Per Share Invested Capital
    PRPH
    ProPhase Labs
    36.76% $0.11 $19.4M
    XWEL
    XWELL
    18.78% -$1.00 $3.4M
  • What do Analysts Say About PRPH or XWEL?

    ProPhase Labs has a consensus price target of $13.80, signalling upside risk potential of 3609.68%. On the other hand XWELL has an analysts' consensus of -- which suggests that it could grow by 586.28%. Given that ProPhase Labs has higher upside potential than XWELL, analysts believe ProPhase Labs is more attractive than XWELL.

    Company Buy Ratings Hold Ratings Sell Ratings
    PRPH
    ProPhase Labs
    0 0 0
    XWEL
    XWELL
    0 0 0
  • Is PRPH or XWEL More Risky?

    ProPhase Labs has a beta of -0.412, which suggesting that the stock is 141.195% less volatile than S&P 500. In comparison XWELL has a beta of 0.866, suggesting its less volatile than the S&P 500 by 13.424%.

  • Which is a Better Dividend Stock PRPH or XWEL?

    ProPhase Labs has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. XWELL offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. ProPhase Labs pays -- of its earnings as a dividend. XWELL pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios PRPH or XWEL?

    ProPhase Labs quarterly revenues are $1.4M, which are smaller than XWELL quarterly revenues of $7M. ProPhase Labs's net income of $4M is higher than XWELL's net income of -$4.7M. Notably, ProPhase Labs's price-to-earnings ratio is -- while XWELL's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for ProPhase Labs is 2.02x versus 0.15x for XWELL. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    PRPH
    ProPhase Labs
    2.02x -- $1.4M $4M
    XWEL
    XWELL
    0.15x -- $7M -$4.7M

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

Will GoodRX Stock Bounce Back?
Will GoodRX Stock Bounce Back?

GoodRX (NASDAQ:GDRX) tracks prescription drug prices and its model was…

Will FCX Benefit From Tariffs?
Will FCX Benefit From Tariffs?

Freeport-McMoRan (NYSE:FCX) is among the world’s largest producers of copper…

Can Levi Stock Double?
Can Levi Stock Double?

Levi Strauss (NYSE:LEVI) is among the oldest clothing brands in…

Stock Ideas

Buy
70
Is NVDA Stock a Buy?

Market Cap: $4.2T
P/E Ratio: 58x

Buy
62
Is MSFT Stock a Buy?

Market Cap: $3.8T
P/E Ratio: 43x

Sell
40
Is AAPL Stock a Buy?

Market Cap: $3.1T
P/E Ratio: 35x

Alerts

Buy
82
SBET alert for Jul 17

SharpLink Gaming [SBET] is down 2.6% over the past day.

Buy
89
EXOD alert for Jul 17

Exodus Movement [EXOD] is down 4.14% over the past day.

Buy
60
U alert for Jul 17

Unity Software [U] is up 7.51% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock